MUSCLE FAT INFILTRATION IS ELEVATED IN PREFRAIL AND MODERATELY PHYSICALLY IMPAIRED PATIENTS – INTERIM RESULTS FROM THE PROSPECTIVE MULTI-CENTER CIRRHOSIS COHORT STUDY ACCESS-ESLD

<div><p><b>Background: </b>Physical frailty and sarcopenia are related but not fully overlapping, and links to outcomes and health care utilization in liver cirrhosis. Physical frailty may be assessed with Liver Frailty Index (LFI) or Short Performance Physical Battery (SPPB), and sarcopenia is typically assessed by measuring muscle size using imaging.</p>

CHARACTERISTICS AND OUTCOMES OF TRANSGENDER PATIENTS WITH CIRRHOSIS: A NATIONAL COHORT STUDY

<div><p><strong>Background</strong>: The American Association for the Study of Liver Diseases has stated that fostering a “supportive environment for transsexual individuals seeking hepatology care” is an important goal. However, the landscape of transgender patients with cirrhosis is largely unknown. We aimed to assess the clinical characteristics of transgender patients with cirrhosis and quantify their outcomes. </p>

POINT-OF-CARE ECHOCARDIOGRAPHY TO ASSESS IMPACT OF CIRRHOTIC CARDIOMYOPATHY AND CARDIORENAL BIOMARKERS IN PATIENTS WITH CIRRHOSIS AND REFRACTORY ASCITES

<div><p><strong><b>Background:</strong> </b></p>
<p>Point-of-care echocardiography (POC-Echo) can be used to evaluate Cirrhotic Cardiomyopathy (CCM) and inferior vena cava (IVC) dynamics. The impact of cardiac function and IVC dynamics on cirrhosis progression towards refractory ascites and HRS-AKI is yet to be defined. This study aims to evaluate the utility of CCM markers and IVC changes, assessed by POC-Echo, in predicting adverse outcomes in patients with cirrhosis and ascites.</p>
<p></p>

A-LINK: UTILIZING A LEARNING HEALTH NETWORK MODEL FOR IMPROVING OUTCOMES IN AUTOIMMUNE HEPATITIS

<div><p><b>Background:</p> </b><p>A-LiNK (Autoimmune Liver disease Network for Kids) is a collaborative, multi-center learning health network uniting patients, parents, clinicians, researchers, and stakeholders to address gaps in care for children with Autoimmune Liver Disease. We seek to define predictors of optimal outcomes and determine current practices in Autoimmune Hepatitis (AIH).</p>

DEVELOPMENT OF A NON-INVASIVE CLASSIFIER (FAST-3) TO PREDICT ADVANCED FIBROSIS IN MASH IN LIEU OF LIVER BIOPSIES IN U.S. ADULTS WITH MASLD

<div><p><strong><b>Background:</strong> </b>Metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and scoring depend on invasive liver biopsies by measuring metabolic dysfunction-associated steatotic liver disease (MASLD) activity score (NAS) and fibrosis score. However, a quantitative estimation of the combined effect of clinically available laboratory measures and transient elastography parameters (controlled attenuation parameter [CAP] and liver stiffness score [LSM]) as a screening / diagnostic test for advanced MASH has been suggested.

Subscribe to